6 results about "Tubulin" patented technology

The present disclosure relates to compositions for increasing acetylated alpha-tubulin levels in peripheral neuronal cells. The present disclosure also relates to the use of tubulin deacetylase inhibitors, or activators of tubulin acetylation for increasing acetylated tubulin levels in the cells. The present disclosure also relates to methods for assessing risk of developing peripheral neuropathy by assessing the levels of acetylated alpha-tubulin. The present disclosure further relates to methods for treating a subject suffering from a peripheral neuropathy using the compositions described herein.

A determination has been made that apicomplexan tubulin, an essential parasite component, is an excellent drug target. Here, it is shown that it is possible to specifically target parasite tubulins, without harming the mammalian host. A compound has been identified that destabilizes specifically parasite MTs and inhibits essential parasite processes of replication and host cell invasion. This provides a new strategy to tackle the issue of drug resistance development. Specifically, the use of the compound parabulin and / or its derivates in the process of targeting protozoan tubulin for the inhibition of the replication of protozoans in mammalian organism, wherein parabulin has the following molecular weight, sum formula, name and structure:MW: 373.4 Da;Formula: C20H23NO6, ⋅Name (s): 3-(3,4-dimethoxyphenyl)-N-[(3,4,5-trimethoxyphenyl)methyl]prop-2-enamide; (2E)-3-(3,4-Dimethoxyphenyl)-N-(3,4,5-trimethoxyphenyl)acrylamid;SMILES:0(C1═C(OC)C═CC(═C1)C═CC(═0)N(CC2═CC(═C(OC)C(═C2)OC)OC)[H])C.

The application relates to the technical field of medicines, and discloses a 4-methyl quinazoline PI3K-Tubulin dual-target inhibitor and a preparation method and application thereof. Specifically disclosed are a PI3K-Tubulin dual-target inhibitor compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition and preparation containing the compound or the pharmaceutically acceptable salt thereof, a method for preparing the compound or the pharmaceutically acceptable salt thereof, and application of the compound or the pharmaceutically acceptable salt thereof in preparing medicines for treating and / or preventing diseases mediated by PI3K-Tubulin and related diseases.

This invention relates to the field of cell biology, and more particularly to a method for constructing an artificial cell model in vitro based on extracts from Xenopus laevis egg cells. The method includes: mixing cytoplasmic extracts from Xenopus laevis egg cells, demembranous sperm, and tubulin, dispersing the mixture in an oil phase to obtain a reconstructed system; reacting the reconstructed system at 20-24°C for at least 30 minutes, resulting in the formation of a phospholipid bilayer-based cytoplasmic membrane structure around the cell. This invention provides a method for constructing artificial cells by selecting cytoplasmic extracts from Xenopus laevis egg cells, adding specific substances, and reacting under specific conditions to allow the extracts to self-assemble into cell structures in vitro, simultaneously forming a cytoplasmic membrane. The method provided by this invention offers important clues to the origin and evolution of cells, and the resulting artificial cell structures are highly similar to normal cells, possessing significant application value.

The present invention involves the conjugation of tubulysin derivatives (analogs) to cell-binding molecules via branched (side chain) linkers, with the resulting conjugates having better pharmacokinetic properties and thus enabling more precise targeting and killing of diseased cells. The present invention also relates to methods for synthesizing the conjugates of tubulysin analogs to cell-binding agents and the molecules involved therein, as well as targeted treatment of cancer, infectious diseases, and autoimmune diseases using the conjugates. Conjugates of tubulysin with long branched linkers extend half-life during targeted delivery and minimize exposure to non-target cells, tissues, or organs in the blood circulation, thereby reducing off-target toxicity.

Compounds comprising a triazole scaffold, compositions comprising same, and the use of such compounds and compositions to inhibit tubulin-associated unit (tau) protein and alpha-synuclein (α-syn) protein aggregation, including neurofibrillary tangles (NFTs) and Lewy bodies.